Blockchain Registration Transaction Record

Soligenix Advances Rare Disease Treatments with Promising Clinical Milestones

Soligenix announces Q1 2025 results & clinical milestones for rare disease treatments, including HyBryte(TM) for CTCL & SGX945 for Behçet’s disease. Learn more.

This news is crucial for patients suffering from rare diseases with limited treatment options, as Soligenix's advancements could lead to new, effective therapies. Investors and stakeholders in the biopharmaceutical sector should also take note, as the company's progress may signal significant developments in the treatment of conditions like CTCL, Behçet’s disease, and psoriasis, potentially opening up new markets and opportunities for growth.